Venous thromboembolism (VTE), defined as either pulmonary embolism (PE) or deep venous thrombosis (DVT), is a rare, but serious complication following total hip arthroplasty (THA). Current VTE guidelines recommend pharmacologic agents with or without intermittent pneumatic compression devices (IPCDs). At our institution, both 81mg aspirin (ASA) twice a day (BID) and portable IPCDs were prescribed to THA patients at standard risk for VTE. The aim of this study is to determine if discontinuing the use of portable outpatient IPCDs is safe and does not increase the rate of VTE in patients undergoing THA. A retrospective review of 1,825 consecutive THA cases was conducted identifying patients with a VTE 90-days postoperatively. Patients were divided into two separate consecutive cohorts. Cohort one consisted of THA patients who received outpatient IPCDs for a period of 14 days (control). Cohort two consisted of THA patients without outpatient IPCDs (experimental). Patients were non-randomized to 81mg ASA BID for 28 days for VTE chemoprophylaxis. An interim power analysis was performed to determine the proper sample size.Introduction
Methods
The Comprehensive Care for Joint Replacement (CJR) initiative was implemented to address the two most commonly billed inpatient surgical procedures, total hip and knee arthroplasty. The primary purpose of this manuscript is to review the economic implications of one institution's mandatory involvement in CJR in comparison to prior involvement in Bundled Payment for Care Improvement (BPCI). The average cost per episode of care (EOC) was calculated using our institution's historical data. The target prices, projected savings or losses per EOC, and the projected annual savings for both BPCI and CJR were established and comparatively analyzed.Introduction
Methods
